Physician profile
Kevin N Kuriakose
NPI 1417188723
$6,318.67
in general payments reported to CMS, 2019-2025
25 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 90% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $121 · 2021: $557 · 2022: $837 · 2023: $1,220 · 2024: $1,777 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,316.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,745.28 | 2019-2025 | Fasenra, Tezspire, Saphnelo |
| Jazz Pharmaceuticals INC. | $912.95 | 2019-2025 | |
| Harmony Biosciences LLC | $672.96 | 2022-2025 | Wakix |
| Glaxosmithkline, LLC. | $538.64 | 2020-2025 | Nucala |
| Genzyme Corporation | $513.94 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $440.36 | 2019-2025 | Dupixent |
| Amgen INC. | $356.69 | 2023-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $240.35 | 2019-2025 | |
| Phadia US INC. | $148.60 | 2021-2025 | Immunocap |
| Genentech USA, INC. | $138.63 | 2019-2025 | Xolair |
| Avadel Cns Pharmaceuticals, LLC | $102.05 | 2024-2025 | Lumryz |
| Covis Pharma Gmbh | $96.78 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $93.09 | 2019 | |
| Electromed, INC. | $51.56 | 2023-2025 | Smartvest |
| Biomarin Pharmaceutical INC. | $39.42 | 2024 | Voxzogo 1.2mg |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.02 | 2022 | |
| Kaleo, INC. | $28.28 | 2024 | Auvi-Q |
| Pharming Healthcare, INC. | $26.96 | 2024 | Ruconest |
| Baxter Healthcare | $24.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.66 | 2022 | |
| Philips North America LLC | $22.65 | 2024 | (Ak6) Vest Therapy |
| Azurity Pharmaceuticals, INC. | $22.47 | 2025 | Alvesco |
| Advanced Respiratory, INC | $18.90 | 2021 | |
| Biogen, INC. | $16.22 | 2022 | |
| Fisher & Paykel Healthcare INC | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kuriakose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.